Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NUVB Stock 12 Month Forecast
Average Price Target
$11.38
▲(26.59% Upside)
| Highest Price Target$18.00 | Average Price Target$11.38 | Lowest Price Target$8.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$10→$18
Buy
100.22%
Upside
Reiterated
12/11/25
Nuvation Bio's IBTROZI Gains Buy Rating Amid Increased Market Penetration and Extended Therapy DurationValuation and Risks. We assess Nuvation Bio using a DCF-based valuation, applying an 11% discount rate and a 1.0% terminal growth rate. As noted above, taletrectinib has been approved in the U.S. for the treatment of ROS1+ NSCLC. We also employ a 29.84% effective corporate tax rate.
Clear Street
$12
Buy
33.48%
Upside
Reiterated
11/26/25
Citizens JMP
$8→$10
Buy
11.23%
Upside
Reiterated
11/20/25
Wedbush
$7→$11
Buy
22.36%
Upside
Reiterated
11/19/25
B. Riley Securities
$12
Buy
33.48%
Upside
Initiated
11/19/25
TD Cowen
―
Buy
―
Reiterated
11/18/25
JonesTrading
$10
Buy
11.23%
Upside
Reiterated
11/18/25
Positive Outlook on Nuvation Bio's Safusidenib Driven by Promising Clinical Data and Strategic FocusWe remain highly optimistic regarding NUVB's exciting second program with safusidenib following their first FDA approval with Ibtrozi. Recall that NUVB acquired safusidenib from the acquisition of AnHeart Therapeutics, who licensed the drug from 2024 (press release). This update from Daiichi (OTCMKTS: DSNKY, Not Rated) helped to better clarify safusidenib's durable efficacy, even if mPFS was not reached, and profile in the non-enhancing tumors. However, we note that it is in enhancing tumors where we saw the first complete responses of any Symbol NUVB Price (Nov 17, 2025) 4.67 Market Cap (MM) 1,606 Dividend NA Enterprise Value (MM) 1,114 Shares/Units Outstanding (MM) 342.833 Dividend Yield NA Free Float (MM) 275.6 Free Float % 80.4% 52-Week Range 1.54—5.55 3-Month Avg. Daily Vol.
RBC Capital
$7→$8
Buy
-11.01%
Downside
Reiterated
11/03/25
Jefferies
$10
Buy
11.23%
Upside
Initiated
09/29/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$10→$18
Buy
100.22%
Upside
Reiterated
12/11/25
Nuvation Bio's IBTROZI Gains Buy Rating Amid Increased Market Penetration and Extended Therapy DurationValuation and Risks. We assess Nuvation Bio using a DCF-based valuation, applying an 11% discount rate and a 1.0% terminal growth rate. As noted above, taletrectinib has been approved in the U.S. for the treatment of ROS1+ NSCLC. We also employ a 29.84% effective corporate tax rate.
Clear Street
$12
Buy
33.48%
Upside
Reiterated
11/26/25
Citizens JMP
$8→$10
Buy
11.23%
Upside
Reiterated
11/20/25
Wedbush
$7→$11
Buy
22.36%
Upside
Reiterated
11/19/25
B. Riley Securities
$12
Buy
33.48%
Upside
Initiated
11/19/25
TD Cowen
―
Buy
―
Reiterated
11/18/25
JonesTrading
$10
Buy
11.23%
Upside
Reiterated
11/18/25
Positive Outlook on Nuvation Bio's Safusidenib Driven by Promising Clinical Data and Strategic FocusWe remain highly optimistic regarding NUVB's exciting second program with safusidenib following their first FDA approval with Ibtrozi. Recall that NUVB acquired safusidenib from the acquisition of AnHeart Therapeutics, who licensed the drug from 2024 (press release). This update from Daiichi (OTCMKTS: DSNKY, Not Rated) helped to better clarify safusidenib's durable efficacy, even if mPFS was not reached, and profile in the non-enhancing tumors. However, we note that it is in enhancing tumors where we saw the first complete responses of any Symbol NUVB Price (Nov 17, 2025) 4.67 Market Cap (MM) 1,606 Dividend NA Enterprise Value (MM) 1,114 Shares/Units Outstanding (MM) 342.833 Dividend Yield NA Free Float (MM) 275.6 Free Float % 80.4% 52-Week Range 1.54—5.55 3-Month Avg. Daily Vol.
RBC Capital
$7→$8
Buy
-11.01%
Downside
Reiterated
11/03/25
Jefferies
$10
Buy
11.23%
Upside
Initiated
09/29/25
Best Analysts Covering Nuvation Bio
1 Month
xxx
Success Rate
11/18 ratings generated profit
Average Return
+9.04%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.11% of your transactions generating a profit, with an average return of +9.04% per trade.
3 Months
xxx
Success Rate
13/18 ratings generated profit
Average Return
+25.43%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +25.43% per trade.
1 Year
Success Rate
13/16 ratings generated profit
Average Return
+120.41%
reiterated a buy rating last month
Copying David Nierengarten's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +120.41% per trade.
2 Years
xxx
Success Rate
18/18 ratings generated profit
Average Return
+183.59%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +183.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NUVB Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
14
9
9
11
9
Buy
3
1
2
8
9
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
10
11
19
18
Each month's total comprises the sum of three months' worth of ratings.
NUVB Financial Forecast
NUVB Stock Forecast FAQ
What is NUVB’s average 12-month price target, according to analysts?
Based on analyst ratings, Nuvation Bio’s 12-month average price target is 11.38.
What is NUVB’s upside potential, based on the analysts’ average price target?
Nuvation Bio has 26.59% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NUVB a Buy, Sell or Hold?
Nuvation Bio has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Nuvation Bio’s price target?
The average price target for Nuvation Bio is 11.38. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $8.00. The average price target represents 26.59% Increase from the current price of $8.99.
The highest analyst price target is $18.00 ,the lowest forecast is $8.00. The average price target represents 26.59% Increase from the current price of $8.99.
What do analysts say about Nuvation Bio?
Nuvation Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of NUVB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.